Active — Not RecruitingNot Applicable

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

United States100 participantsStarted 2014-10-13

Plain-language summary

This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week * Patients with renal function (estimated glomerular filtration rate \[eGFR\] \>= 30) * Any disease type Exclusion Criteria: * Pregnant women * Patients with impaired renal function (eGFR \< 30) * Patients with surgical implants and/or metallic foreign bodies non-compatible with the MR magnet * Patients with contraindications to the use of intravenous contrast such as allergic type reactions

What they're measuring

Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI)

Timeframe: Up to 4 years

Trial details

NCT IDNCT02156739

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials